SCA
GSK icon

Salient Capital Advisors’s GSK GSK Stock Holding History

Salient Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,856
Closed -$423K – 111
2017
Q2 		$423K Sell
7,856
-5,096
-39% -$272K 0.01% 162
2017
Q1 		$683K Sell
12,952
-1,100
-8% -$55.8K 0.01% 158
2016
Q4 		$676K Buy
14,052
+144
+1% +$7.11K 0.01% 151
2016
Q3 		$750K Buy
13,908
+5,416
+64% +$297K 0.02% 129
2016
Q2 		$460K Buy
+8,492
New +$447K 0.01% 174
2015
Q3 		– Sell
-6,818
Closed -$355K – 257
2015
Q2 		$355K Buy
+6,818
New +$384K 0.01% 206

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Salient Capital Advisors's GSK Position: Q3 2017 in Review

Salient Capital Advisors sold out of GSK (GSK) in Q3 2017, closing a stake of 7,856 shares — an estimated $423K sold.

Salient Capital Advisors first reported a position in GSK in Q2 2015 and held it in 6 quarters. The position peaked at $750K in Q3 2016. 741 funds tracked by Wall St. Rank hold GSK as of Q3 2017.

  • Salient Capital Advisors reported no remaining GSK position as of Q3 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 7,856 GSK shares in Q3 2017, an estimated $423K.
  • Salient Capital Advisors first reported a position in GSK in Q2 2015 and held it in 6 quarters.
  • Salient Capital Advisors's GSK position peaked at $750K in Q3 2016.
  • 741 funds tracked by Wall St. Rank held GSK as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.